论文部分内容阅读
目的 探讨在晚期胰腺癌患者临床治疗中应用替吉奥联合阿帕替尼治疗的临床价值。方法 将62例本院于2015年6月至2017年12月收治的晚期胰腺癌患者为研究对象，以治疗药物差异为分组原则进行分组，对照组行阿帕替尼单药治疗，观察组行替吉奥联合阿帕替尼治疗，对比不同时段两组患者无进展生存率、治疗前后肿瘤标志物水平及生活质量。结果 观察组3、6、9、12个月无进展生存率分别为83.8%、77.4%、58.0%、22.5%，对照组分别为61.2%、51.6%、32.2%、6.4%，P＜0.05。经治疗后，观察组CA-“,”Objective To evaluate the clinical value of the combination of diageo and apatinib in the treatment of patients with advanced pancreatic cancer.Methods A total of 62 patients in our hospital in June 2015 to June 2017 with advanced pancreatic cancer treated as the research object，treatment differences as grouping principle，set up the control line path for monotherapy，set line observation group for go now joint path for treatment，observation compared two groups of patients in the different periods progression-free survival rate，tumor marker levels before and after the treatment，the quality of life.Results The progression-free survival rates at 3，6，9 and 12 months in the observation group were 83.8%，77.4%，58.0% and 22.5%，the control group was 61.2%，51.6%，32.2% and 6.4%，respectively(P＜0.05).After treatment，CA-199，CA242，CEA and CA50 in the observation group were significantly lower than those in the control group，but there were no significant differences(P＞0.05).The scores of quality of life in the observation group were higher after treatment，P＜0.05.Conclusion It is recommended to adopt the combination of gio and apatinib in the treatment of patients with advanced pancreatic cancer，which can improve the progression-free survival rate and improve the quality of life of patients.